FDA Hits Arog Pharmaceuticals With Untitled Letter Over Promotional Tactics

The FDA issued an untitled letter to Arog Pharmaceuticals for promotional claims it made on a display booth and a webpage about an unapproved investigational new drug’s safety and efficacy.
Source: Drug Industry Daily